These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1361441)

  • 21. Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia.
    Neisewander JL; Castañeda E; Davis DA
    Psychopharmacology (Berl); 1994 Sep; 116(1):79-84. PubMed ID: 7862934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
    Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?
    Maj J; Rogóz Z; Skuza G
    J Neural Transm (Vienna); 1999; 106(11-12):1063-73. PubMed ID: 10651103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.
    Visanji NP; Millan MJ; Brotchie JM
    Exp Neurol; 2006 Nov; 202(1):85-92. PubMed ID: 16814282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications.
    Braun AR; Laruelle M; Mouradian MM
    J Neural Transm (Vienna); 1997; 104(4-5):341-62. PubMed ID: 9295170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The selective dopamine antagonist properties of BRL 34778: a novel substituted benzamide.
    Brown F; Campbell W; Clark MS; Graves DS; Hadley MS; Hatcher J; Mitchell P; Needham P; Riley G; Semple J
    Psychopharmacology (Berl); 1988; 94(3):350-8. PubMed ID: 3128811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson's disease?
    Brooks S; Kaur S; Starr BS; Starr MS
    J Neural Transm (Vienna); 1996; 103(6):737-48. PubMed ID: 8836935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo antagonism of the behavioral responses to L-3-,4-dihydroxyphenylalanine by L-3-,4-dihydroxyphenylalanine cyclohexyl ester in conscious rats.
    Matsushita N; Misu Y; Goshima Y
    Eur J Pharmacol; 2009 Mar; 605(1-3):109-13. PubMed ID: 19168057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered dopamine and serotonin metabolism in the dopamine-denervated and serotonin-hyperinnervated neostriatum of adult rat after neonatal 6-hydroxydopamine.
    Molina-Holgado E; Dewar KM; Descarries L; Reader TA
    J Pharmacol Exp Ther; 1994 Aug; 270(2):713-21. PubMed ID: 8071864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
    J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats.
    Agovic MS; Yablonsky-Alter E; Lidsky TI; Banerjee SP
    Eur J Pharmacol; 2008 Jun; 587(1-3):181-6. PubMed ID: 18457824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.
    Hill MP; Brotchie JM
    Br J Pharmacol; 1999 Dec; 128(7):1577-85. PubMed ID: 10602339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
    Eskow KL; Gupta V; Alam S; Park JY; Bishop C
    Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of single and multiple treatments with L-dihydroxyphenylalanine (L-DOPA) on dopamine receptor-G protein interactions and supersensitive immediate early gene responses in striata of rats after reserpine treatment or with unilateral nigrostriatal lesions.
    Khan SM; Smith TS; Bennett JP
    J Neurosci Res; 1999 Jan; 55(1):71-9. PubMed ID: 9890435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis.
    Sabol KE; Seiden LS
    Brain Res; 1998 Sep; 806(1):69-78. PubMed ID: 9739110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
    Van De Witte SV; Groenewegen HJ; Voorn P
    Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of acute tyrosine depletion in using a branched chain amino-acid mixture on dopamine neurotransmission in the rat brain.
    Le Masurier M; Oldenzeil W; Lehman C; Cowen P; Sharp T
    Neuropsychopharmacology; 2006 Feb; 31(2):310-7. PubMed ID: 16034439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Behavioral, biochemical, and histochemical analyses of the central effects of monoamine precursors after peripheral decarboxylase inhibition.
    Butcher LL; Engel J; Fuxe K
    Brain Res; 1972 Jun; 41(2):387-411. PubMed ID: 4402607
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects on general behaviour and neurotransmitter functions of a new 5-hydroxytryptamine3 receptor antagonist with potential therapeutic relevance in central nervous system disturbances.
    Rizzi CA; Prudentino A; Giraldo E
    Arzneimittelforschung; 1993 Oct; 43(10):1033-41. PubMed ID: 7903536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
    Segovia G; Mora F; Crossman AR; Brotchie JM
    Mov Disord; 2003 Feb; 18(2):138-49. PubMed ID: 12539206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.